Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | ADH1A | P07327 | 1/20 | 0.37 |
| ▸ | ADH4 | P08319 | 1/20 | 0.37 |
| ▸ | ADH7 | P40394 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006883 | 1.00 | SPHK1 (0.46) | SPHK1SPHK2HDAC1HDAC3HDAC2 | |
| SCHEMBL4280721 | 0.98 | SPHK1 (0.43) | SPHK1SPHK2HDAC1HDAC3HDAC2 | |
| Iodide SCHEMBL5325544 | 0.96 | SPHK1 (0.41) | SPHK1SPHK2HDAC1HDAC3HDAC2 | |
| SCHEMBL3166180 | 0.91 | — | — | |
| Acetic Acid SCHEMBL5849280 | 0.91 | HDAC3 (0.43) | SPHK1SPHK2HDAC1HDAC3HDAC2 | |
| Iodide SCHEMBL28722729 | 0.89 | SPHK2 (0.38) | SPHK1SPHK2HDAC1HDAC3HDAC2 | |
| Hydrochloric Acid SCHEMBL28575898 | 0.88 | FAAH (0.47) | — | |
| Octanoic Acid SCHEMBL5848069 | 0.86 | GPR84 (0.55) | HDAC11ALDH1A1TSHR | |
| Hexanoate SCHEMBL5847711 | 0.86 | GPR84 (0.55) | HDAC11ALDH1A1TSHR | |
| Decanoic Acid SCHEMBL5849865 | 0.86 | GPR84 (0.55) | HDAC11ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0918750-B1 | NEW GUANIDINE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | CANCER RES VENTURES LTD (GB) | 2002-08-14 | — | — | EP | claimed |
| US-6284798-B1 | ALKYLAMINOGUANDINES | CANCER RESEARCH VENTURES LIMITED (GB) | 2001-09-04 | — | — | US | claimed |
| US-7078566-B2 | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | BIOSPHINKS AKTIENGESELLSCHAFT (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20040192717-A1 | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | BIOSPHINGS AKTIENGESELLSCHAFT (DE) | 2004-09-30 | — | — | US | disclosed |
| US-6444706-B2 | ANTIINFLAMMATORY AGENTS; MICROBIOCIDES; ANTITUMOR AGENTS; VIRICIDES | CANCER RESEARCH VENTURES LIMITED (GB) | 2002-09-03 | — | — | US | disclosed |
| EP-0918750-B1 | NEW GUANIDINE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | CANCER RES VENTURES LTD (GB) | 2002-08-14 | — | — | EP | disclosed |
| US-20010025055-A1 | New guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions | AMTMANN EBERHARD (DE) | 2001-09-27 | — | — | US | disclosed |
| US-20010023251-A1 | Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions | BIOSPHINGS AG (DE) | 2001-09-20 | — | — | US | disclosed |
| US-6284798-B1 | ALKYLAMINOGUANDINES | CANCER RESEARCH VENTURES LIMITED (GB) | 2001-09-04 | — | — | US | disclosed |
| EP-0918750-A1 | NEW GUANIDINE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | Amtmann, Eberhard (DE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997045401-A1 | NEW GUANIDINE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM KG (DE) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025055-A1 | New guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions | GMPS, GANC, GUCY1A2 | SPHK1 2324/4885SPHK2 2309/4885HDAC1 3932/4885 |
| US-20010023251-A1 | Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions | GMPS, GANC, GUCY1A2 | SPHK1 2473/4885SPHK2 2608/4885HDAC1 4031/4885 |
| US-20040192717-A1 | Salts of guanidine derivatives and pharmaceutical preparations consisting thereof | ODC1, GANC, AOC2 | SPHK1 3208/4885SPHK2 3363/4885HDAC1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.